A meta-analysis [60] investigating Erlo+Bev compared with monotherapy for NSCLC found no substantial benefits for the OS or PFS of all patients, but the combination treatment significantly enhanced OS for EGFR-mutant patients. Here, EGFR is linked to non-small cell lung carcinoma.